The vasculature suffers damage as a result of diabetes, often leading to conditions such as kidney failure. In bench to bedside, Christian Rask-Madsen and George King examine endogenous factors that protect against damage of the vasculature, such as vascular-endothelial growth factor (VEGF). Recent studies report that VEGF is expressed by kidneys and fends off renal failure; such findings have implications for the development of treatments that harness endogenous factors and sound a note of caution for the therapeutic use of VEGF inhibitors. People with end-stage renal disease often die of cardiovascular complications and clinical studies have shown that one popular class of drugs, statins, does not work in this population. In bedside to bench, S. Ananth Karumanchi and Ravi Thadhani show how this clinical finding is spurring research into the biological mechanisms behind cardiovascular death in people with kidney disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Isaac Stillman
References
Brown, M.S. & Goldstein, J.L. Science 272, 629 (1996).
Fellström, B.C. et al. N. Engl. J. Med. 360, 1395–1407 (2009).
Lindner, A., Charra, B., Sherrard, D.J. & Scribner, B.H. N. Engl. J. Med. 290, 697–701 (1974).
Sarnak, M.J. et al. Circulation 108, 2154–2169 (2003).
Wanner, C. et al. N. Engl. J. Med. 353, 238–248 (2005).
Liu, Y. et al. J. Am. Med. Assoc. 291, 451–459 (2004).
Buzello, M. et al. J. Am. Soc. Nephrol. 14, 311–316 (2003).
Wang, Z. et al. Nat. Med. 13, 1176–1184 (2007).
Boaz, M. et al. Lancet 356, 1213–1218 (2000).
Tepel, M., van der Giet, M., Statz, M., Jankowski, J. & Zidek, W. Circulation 107, 992–995 (2003).
Stenvinkel, P. et al. Clin. J. Am. Soc. Nephrol. 3, 505–521 (2008).
Foley, R.N. et al. Kidney Int. 47, 186–192 (1995).
Thadhani, R. J. Am. Soc. Nephrol. 20, 2285–2290 (2009).
Kennedy, D.J. et al. Hypertension 47, 488–495 (2006).
Rabkin, R. et al. J. Am. Soc. Nephrol. 19, 1774–1783 (2008).
Siedlecki, A.M., Jin, X. & Muslin, A.J. Kidney Int. 75, 800–808 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.T. has a research grant from Abbott to conduct a randomized trial using vitamin D in individuals with kidney disease.
Rights and permissions
About this article
Cite this article
Karumanchi, S., Thadhani, R. Kidney complications: Why don't statins always work?. Nat Med 16, 38–40 (2010). https://doi.org/10.1038/nm0110-38
Issue Date:
DOI: https://doi.org/10.1038/nm0110-38
This article is cited by
-
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease
Kidney International (2015)
-
The Authors Reply
Kidney International (2014)
-
Journal Club
Kidney International (2010)
